Drugs / Deoxyspergualin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT00434850 | Oct 2006 → Sep 2011 | type 1 diabetes mellitus | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00001984 | Nov 1999 → Jun 2008 | kidney disorder, transplant rejection | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT01052259 | Jun 2009 → Dec 2012 | chronic transplant rejection | Nippon Kayaku Co., Ltd. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Deoxyspergualin | “the immunosuppressive drug deoxyspergualin (DSG)” NCT00001984 ↗ |
| Known as | DSG | “the immunosuppressive drug deoxyspergualin (DSG)” NCT00001984 ↗ |
| Action | Inhibit | “Deoxyspergualin inhibits the NFkB pathway thus preventing monocyte and macrophage activation.” NCT00001984 ↗ |
| Route | Intravenous | “The DSG infusion will be administered over 3 hours” NCT00434850 ↗ |